This is the protocol for a review and there is no abstract. The objectives are as follows:, In term and near-term newborns (> 34 weeks gestational age) with PPHN, is mortality or the use of backup iNO or ECMO reduced without adverse neurodevelopmental outcome by the use of magnesium sulfate compared with:, Placebo or standard ventilator management alone, Sildenafil infusion, Adenosine infusion, Inhaled nitric oxide, Subgroup analysis will be performed on the basis of diagnosis of PPHN:, Echocardiographic diagnosis versus criteria defining severity of the hypoxia or pre and postductal gradient, Ventilator support versus no ventilator support